Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia (Leukemia, (2022), 36, 4, (1171-1175), 10.1038/s41375-021-01485-x)

Sharman, J. P.; Egyed, M.; Jurczak, W.; Skarbnik, A.; Pagel, J. M.; Flinn, I. W.; Kamdar, M.; Munir, T.; Walewska, R.; Corbett, G.; Fogliatto, L. M.; Herishanu, Y.; Banerji, V.; Coutre, S.; Follows, G.; Walker, P.; Karlsson, K.; Ghia, P.; Janssens, A.; Cymbalista, F.; Woyach, J. A.; Ferrant, E.; Wierda, W. G.; Munugalavadla, V.; Yu, T.; Wang, M. H.; Byrd, J. C.

doi:10.1038/s41375-024-02487-1

Correction to: Leukemiahttps://doi.org/10.1038/s41375-021-01485-x, published online 01 January 2022 The wrong Supplementary file was originally published with this article; it has now been replaced with the correct file. The original article has been corrected.

Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia (Leukemia, (2022), 36, 4, (1171-1175), 10.1038/s41375-021-01485-x) / Sharman, J.P., Egyed, M., Jurczak, W., Skarbnik, A., Pagel, J.M., Flinn, I.W., Kamdar, M., Munir, T., Walewska, R., Corbett, G., Fogliatto, L.M., Herishanu, Y., Banerji, V., Coutre, S., Follows, G., Walker, P., Karlsson, K., Ghia, P., Janssens, A., Cymbalista, F., et al.. - In: LEUKEMIA. - ISSN 0887-6924. - 39:2(2025), pp. 529-529. [10.1038/s41375-024-02487-1]